a

3S Corporation is one of India’s leading stockist, exporter & wholesaler for Anti-cancer drug & Oncology medicines. We even supply & export Sex Enhancement Drugs, Cardiac & Anti Diabetic Medicines. We are a registered wholesaler & exporter for pharmaceutical products licensed by our FDA and Drug Controller in India. Our license number are 20-B/MZ6-23015 & 21-B/ MZ6-23016.

+(91)-(22)-42643060

3scorp.india@gmail.com
Andheri East, Mumbai - 400099, India.

DISCLAIMER

All the pharmaceutical products we offer are prescription drugs and should be used/taken under proper medical guidance and advice. Do not share the medicine with others, since they may be suffering from a problem that is not effectively treated by this drug. We are not an online pharmacy . We do not recommend any drug or give medical advice. We only express opinions and provide information. Whether a medication is right for you is a decision between you and the prescribing doctor. Kindly seek medical advice from a registered doctor 0r hospital/Institution before taking any of these medicines.

Monday - Saturday

10.00 - 19.00

+(91)-(22)-42643060

3scorp.india@gmail.com

Andheri East

Mumbai – 400099, India.

Methylene Blue 1% Injection

  •  prescription drug
Category:

Description

Methylene Blue Injection is a prescription drug used in the treatment of Methaemoglobinaemia. Its active ingredient is methylene blue trihydrate (3,7-Bis(dimethylamino)phenazathionium chloride trihydrate).

In patients with methaemoglobinaemia, therapeutic doses of methylene blue can lower the levels of methaemoglobin in red blood cells. It activates a normally dormant reductase enzyme system that reduces the methylene blue to leucomethylene blue, which in turn is able to reduce methaemoglobin to haemoglobin. However, in large doses, methylene blue can itself produce methaemoglobinaemia and the methaemoglobin concentration should therefore be closely monitored during treatment. Methylene blue is not effective for the treatment of methaemoglobinaemia in patients with glucose-6-phosphate dehydrogenase deficiency as these patients have a diminished capacity to reduce methylene blue to leucomethylene blue. It is also potentially harmful as patients with glucose-6-phosphate dehydrogenase deficiency are particularly susceptible to the haemolytic anaemias induced by methylene blue.

Methylene Blue Solution for Injection is indicated:

  • For the treatment of drug-induced methaemoglobinaemia
  • For the treatment of idiopathic methaemoglobinaemia (in which a structural
  • abnormality of haemoglobin is not present)
  • As a bacteriological stain
  • As a dye in diagnostic procedures such as fistula detection
  • For the delineation of certain body tissues during surgery.

Additional Information

Side Effects

Pack Size